ArticleScientific reports2025
Transcriptomic exploration of key genes related to mitochondria and ferroptosis in inflammatory bowel disease and experimental validation.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Inflammatory bowel disease (IBD) is a systemic condition with multifactorial origins. Mitochondria and ferroptosis have been implicated in the disease, but their potential interaction in IBD remains unclear. Therefore, investigating the relationship between IBD and these factors, along with elucidating the underlying mechanisms, is essential. Differentially expressed genes (DEGs) from the GSE75214 dataset were intersected with mitochondria-related genes (MRGs) and ferroptosis-related genes (FRGs) retrieved from literature to identify candidate genes. Key genes were finalized through machine learning, receiver operating characteristic (ROC) analysis, and expression validation. Subsequently, an artificial neural network (ANN) disease prediction model based on these key genes was constructed and evaluated. Further analyses included enrichment analysis of key genes, immune infiltration analysis, chromosomal localization, and drug prediction. Finally, the expression levels of key genes were validated using reverse transcription quantitative real-time PCR (RT-qPCR). Four genes (AQP8, ACSF2, ACSL4, and IL1B) were identified as key genes. The ANN model demonstrated a strong association between these key genes and IBD, with reliable performance (GSE75214: area under the curve (AUC) = 0.855; GSE59071: AUC = 0.859). Additionally, adaptive immune response, tricarboxylic acid (TCA) cycle, and inositol phosphate metabolism were found to be associated with these key genes in IBD. Specifically, ACSL4 showed the strongest positive correlation with immature dendritic cells (correlation coefficient (cor) = 0.93, p < 0.01), while ACSF2 exhibited the strongest negative correlation with effector memory CD8⁺ T cells (cor = -0.81, p < 0.01). The key genes were localized to different chromosomes. Potential therapeutic drugs for IBD, such as 1-methyl-3-isobutylxanthine, were identified through target drug prediction. RT-qPCR experiments confirmed that AQP8 and ACSF2 expression levels were significantly reduced in IBD (p < 0.01), whereas ACSL4 and IL1B expression levels were significantly increased (p < 0.05). AQP8, ACSF2, ACSL4, and IL1B were identified as key genes in IBD, providing a foundation for future therapeutic research on this disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.